| First Author | Roda AR | Year | 2020 |
| Journal | Int J Mol Sci | Volume | 21 |
| Issue | 18 | PubMed ID | 32927795 |
| Mgi Jnum | J:352667 | Mgi Id | MGI:7704306 |
| Doi | 10.3390/ijms21186630 | Citation | Roda AR, et al. (2020) Both Amyloid-beta Peptide and Tau Protein Are Affected by an Anti-Amyloid-beta Antibody Fragment in Elderly 3xTg-AD Mice. Int J Mol Sci 21(18) |
| abstractText | Alzheimer's disease (AD) is the most common dementia worldwide. According to the amyloid hypothesis, the early accumulation of the Abeta-peptide triggers tau phosphorylation, synaptic dysfunction, and eventually neuronal death leading to cognitive impairment, as well as behavioral and psychological symptoms of dementia. ScFv-h3D6 is a single-chain variable fragment that has already shown its ability to diminish the amyloid burden in 5-month-old 3xTg-AD mice. However, tau pathology is not evident at this early stage of the disease in this mouse model. In this study, the effects of scFv-h3D6 on Abeta and tau pathologies have been assessed in 22-month-old 3xTg-AD mice. Briefly, 3xTg-AD female mice were treated for 2 weeks with scFv-h3D6 and compared with 3xTg-AD and non-transgenic (NTg) mice treated with PBS. The treatment with scFv-h3D6 was unequivocally effective in reducing the area of Abeta staining. Furthermore, a tendency for a reduction in tau levels was also observed after treatment that points to the interplay between Abeta and tau pathologies. The pro-inflammatory state observed in the 3xTg-AD mice did not progress after scFv-h3D6 treatment. In addition, the treatment did not alter the levels of apolipoprotein E or apolipoprotein J. Thus, a 2-week treatment with scFv-h3D6 was able to reduce AD-like pathology in elderly 3xTg-AD female mice. |
